An observational study in Skin Aging and Horizontal Neck Lines, sponsored by PharmaResearch Co.,Ltd. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by PharmaResearch Co.,Ltd · Observational
The goal of this clinical study is to evaluate changes in the appearance of horizontal neck lines after treatment with DOT PN (Rejuran S), a polynucleotide-based injectable medical device, administered using a dual-plane injection technique in adults aged 25 to 65 years with mild to moderate horizontal neck lines.
The main question it aims to answer is:
- What is the mean change in horizontal neck wrinkle depth from the start of the study (Week 0) to Week 16, as measured by 3D imaging?
All participants will receive the same study treatment; there is no comparison group. Participants will:
The injection technique, including the use of a blunt-tip cannula for the deeper layer, is a study-specific procedure defined by the study protocol and standardized across all study sites.
PharmaResearch Co.,Ltd is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults aged 25 to 65 years with horizontal neck lines graded 1 to 3 on the Horizontal Neck Wrinkle Severity (HNWS) scale, enrolled at the participating study sites in Thailand, Singapore, and Malaysia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Polynucleotide-based injectable medical device supplied in 1.0 mL prefilled syringes. Each session uses 4.0 mL in total (four 1.0 mL syringes), for 4 sessions at 4-week intervals (Weeks 0, 4, 8, and 12). Injections follow a study-specific dual-plane technique for horizontal neck lines: a superficial plane using a 30G sharp needle and a deeper plane using a 25G blunt-tip cannula introduced through a 23G guide needle. The cannula-based deeper-plane injection is a study-specific procedure and differs from the needle-based injection method described in the product's instructions for use.
Also known as: Rejuran S, Polynucleotide (PN)
Change From Baseline in Horizontal Neck Wrinkle Depth at Week 16
Mean change in horizontal neck wrinkle depth from Baseline (Week 0) to Week 16 (4 weeks after the final treatment session), measured by QuantifiCare 3D imaging.
Time frame: Baseline (Week 0) and Week 16
Change From Baseline in Horizontal Neck Wrinkle Depth at Weeks 20 and 24
Mean change in horizontal neck wrinkle depth from Baseline to Week 20 and Week 24, measured by QuantifiCare 3D imaging.
Time frame: Baseline (Week 0), Week 20, and Week 24
Investigator-Assessed Global Aesthetic Improvement Scale (GAIS) Score at Weeks 16, 20, and 24
Global Aesthetic Improvement Scale (GAIS) score assessed by the Investigator using the GAIS 5-point scale at Week 16, Week 20, and Week 24.
Time frame: Week 16, Week 20, and Week 24
FACE-Q Appraisal of Neck Scale Score at Weeks 16, 20, and 24
Participant-reported outcome measured using the FACE-Q Aesthetics Module scale at Week 16, Week 20, and Week 24.
Time frame: Week 16, Week 20, and Week 24
Incidence and Severity of Adverse Events (AEs) and Adverse Device Effects (ADEs)
Incidence and severity of Adverse Events (AEs) and Adverse Device Effects (ADEs) reported throughout the study period, from Screening through Week 24.
Time frame: From Screening through Week 24
Change From Baseline in Horizontal Neck Wrinkle Severity (HNWS) Grade at Weeks 16, 20, and 24
Change in Horizontal Neck Wrinkle Severity (HNWS) grade from Baseline (Week 0) to Week 16, Week 20, and Week 24, assessed by the Investigator.
Time frame: Baseline (Week 0), Week 16, Week 20, and Week 24
Plan to share: No — There is currently no plan to make individual participant data (IPD) available to other researchers.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
PharmaResearch Co.,Ltd